Cognitive function in patients on androgen suppression: A prospective, multicentric study
Por:
Morote J, Tabernero ÁJ, Álvarez-Ossorio JL, Ciria JP, Domínguez-Escrig JL, Vázquez F, Angulo J, López FJ, de La Iglesia R and Romero J
Publicada:
1 mar 2018
Categoría:
Urology
Resumen:
Objective: To assess the effect of androgen deprivation therapy (ADT) on cognitive performance (CP) in patients with prostate cancer (PCa) after 6 months of treatment with luteinizing hormone-releasing hormone (LHRH) analogues.
Material and methods: Prospective, observational, multicentre, open-label study of patients diagnosed with nonmetastatic or asymptomatic metastatic PCa scheduled to receive LHRH analogues for >= 6 months. We assessed four CP domains at baseline and after 6 months of ADT: 1) Working memory: Wechsler Adult Intelligence Scale III (WAIS III) Digit Span Subtest (WAIS ill-Digit); 2) Visual memory: ad hoc visual memory test; 3) Visuospatial ability: Judgement of Line Orientation (JLO) and Mental Rotation of Three-Dimensional Objects (3D-Rotation); and 4) Nonverbal analytical reasoning: WAIS III Matrix Reasoning Test (WAIS III-MRT). Changes outside the baseline 95% confidence intervals were considered significant.
Results: A total of 308 patients completed the study. Of these, 245 (79.6%) experienced no statistically significant changes on any test and 63 patients (20.4%) experienced significant changes in >= 1 test. Of these, most presented a change in only one test, distributed evenly between improvements (58 patients; 18.8%) and worsening (56 patients; 18.2%). For individual tests, most patients (87.8% to 91.8%) had no change from baseline; however, the significant changes (improvement vs. deterioration, respectively) were as follows: WAIS III-Digit (6.3% vs. 5.9%); visual memory (5.3% vs. 5.7%); JLO (5.3% vs. 4.5%); 3D-Rotation (4.1%vs. 4.1%); and WAIS III-MRT (4.8% vs. 5.8%).
Conclusions: CP in patients with PCa does not appear to be adversely affected by 6 months of LHRH analogue administration. (C) 2017 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
Morote J:
Departamento de Urología, Hospital Universitario Vall d'Hebron, Barcelona, España
Tabernero ÁJ:
Departamento de Urología, Hospital Universitario La Paz, Madrid, España
Álvarez-Ossorio JL:
Departamento de Urología, Hospital Universitario Puerta del Mar, Cádiz, España
Ciria JP:
Departamento de Oncología Radioterápica, Hospital Universitario Donostia, San Sebastián, España
Domínguez-Escrig JL:
Departamento de Urología, Instituto Valenciano de Oncología, Valencia, España
Vázquez F:
Departamento de Urología, Hospital Universitario Virgen de las Nieves, Granada, España
Angulo J:
Departamento de Urología, Hospital Universitario de Getafe, Madrid, España
López FJ:
Departamento de Oncología Radioterápica, Hospital Universitario Virgen de la Arrixaca , Murcia, Spain
de La Iglesia R:
Departamento de Urología, Hospital Rafael Méndez, Murcia, España
:
Urología. Hospital Universitario Sant Joan d'Alacant, Alicante, España
|